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Abstract As antifungal agents are frequently used in hema-
tology andoncology, economic dataon the empiricaltherapy of
suspected systemic fungal infection are pivotal. Data were
analyzed according to: (1) the rate of nephrotoxicity related to
treatment with caspofungin in comparison to liposomal
amphotericin B (L-AmB) from a randomized clinical trial, (2)
the effect of nephrotoxicity on length of hospital stay from a
European observational study, and (3) an example of total
bottom-up cost in a department of hematology in Germany. All
estimates include 95% confidence intervals (CI) using two-
stage Monte Carlo simulation on binominal and Gaussian
random variables from separate studies with comparable
populations. Overall, 8.9 (95% CI 5.9–12.1) fewer patients
(of 100 randomized) experienced worsening of renal function
with caspofungin vs L-AmB, giving a number needed to treat
for one patient to be harmed by L-AmB of 12 (95% CI 8–17).
This was estimated to translate into 5.3 extra days in hospital
(95% CI 1.6–9.1) per event or 0.48 days (95% CI 0.14–0.88)
worth €298 (95% CI 89–554) per patient receiving L-AmB
rather than caspofungin. From the hospital perspective, use of
caspofungin was estimated to be cost-neutral compared to L-
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(*)AmB at a per diem total hospital cost of €428 with, and €1284
without, consideration of supplementary reimbursement
(Zusatzentgelt) of both L-AmB and caspofungin. The data
presented in this scenario show that use of caspofungin in
hematology–oncology departments in Germany results in
shorter hospital stays and is at least cost-neutral compared to
use of L-AmB.
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Introduction
Patients with hematological disorders are at considerable
risk for systemic fungal infections [1–3]. In particular,
infections caused by organisms of the genera Aspergillus
and Candida are an increasingly recognized threat to
immunocompromised patients. This results in a high burden
to the European healthcare system [1–4].
Early clinical diagnosis of invasive fungal infection is
difficult due to the non-specific clinical picture and the
plethora of risk factors [3]. Microbiological challenges
include availability of tissue, cytology and cultures, and/or
non-specific microbiological culture results [1]. Radiolog-
ical confirmation of diagnosis can be delayed due to the
limitations of chest radiographs, and the specificity of CT
scans can be limited [5, 6].
To overcome these issues, the concept of empirical therapy
of suspected fungal infection has been established for patients
at risk of infection who show persistent fever of unknown
origin despite broad-spectrum antibiotic therapy [3].
At present, liposomal amphotericin B (L-AmB) and
caspofungin are approved for empirical therapy of suspected
fungal infection. In a randomized controlled trial (RCT) in
patients with persistent fever and neutropenia, the efficacy of
caspofungin was recently found to be non-inferior to that of L-
AmB [7]. In addition, caspofungin was found to be far better
tolerated than L-AmB in terms of nephrotoxicity (2.6 vs
11.5%; p<0.001) [7]. The occurrence of nephrotoxicity in
association with liposomal and other formulations of AmB
has been shown to prolong the length of hospital stay in
Europe by an average of 5.3 days [8]. No concrete economic
data are available as yet on the financial impact of this on
hospitals that treat these patients [4]. However, now that
reimbursement of services in different countries is increas-
ingly being based on diagnostic-related groups (DRGs), the
economic impact on the economics of less tolerable agents on
hematology–oncology departments could be considerable.
The objective of the study was to evaluate the bottom-up
costs and the clinical consequences of empirical therapy of
suspected systemic fungal infection from the perspective of a
department of hematology of a German tertiary care hospital.
Materials and methods
Summary of clinical trials
Head-to-head trial caspofungin vs L-AmB
In a recently published double-blind RCT performed in
hematology–oncology patients with persistent fever and
neutropenia, the efficacy of caspofungin was found to be
non-inferior to that of L-AmB [7]. In this trial, 556 patients
received caspofungin and 539 received L-AmB (mean
duration, 13 and 12.5 days, respectively). In most of the
patients, the underlying condition was acute myeloid
leukemia (AML), diagnosed in 364 caspofungin patients
(65.5%) and 339 L-AmB patients (62.9%). The primary
efficacy endpoint, a favorable overall response, was
achieved by 33.9% of patients in the caspofungin group
and 33.7% in the L-AmB group (95.2% CI −5.6, 6.0) [7].
Nephrotoxicity [defined as doubling of the serum creatinine
level or, if the serum creatinine level was elevated at
enrolment, an increase of at least 1 mg per deciliter
(88 μmol per liter)] formed part of the safety analyses.
There was less nephrotoxicity (2.6% of patients treated with
caspofungin vs 11.5% of patients treated with L-AmB, p<
0.001) [7].
European study on use of various formulations
of amphotericin B
Very recently, data of a prospective longitudinal evaluation
of antifungal drugs (LEAD) study performed in 418
European adults with suspected, probable, or proven
invasive fungal infection with various formulations of
AmB have been published [8]. In the majority of cases,
the underlying disease was leukemia or lymphoma (81%).
Length of hospital stay was significantly prolonged
(5.3 days) in patients who developed nephrotoxicity
(creatinine value in the peripheral blood ≥1.5 times greater
than baseline) while on AmB formulations [8].
Direct cost of hospital stay in a department of hematology
in Germany
The background for the economic analysis was a bottom-up
study to investigate hospital care (including day clinic)
costs in all patients aged 16 to 60 years with AML
receiving standard chemotherapy at the hematology unit,
First Department of Medicine, Bonn University, a German
tertiary care hospital in 2002. Demographic variables,
information on disease status and length of hospital stay,
and direct medical and non-medical costs were documented
retrospectively by chart review. Components of the per
diem costs relating to housing and general charges were
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treatment costs associated with individual patients [9, 10].
The cost of a day of institutional care was calculated on the
basis of the annual case-load of the entire institution or of
the individual department, where applicable. The following
depleted resources were identified, measured, and valued in
descriptive fashion (Table 1)[ 11]: (1) medical care by
healthcare professionals and its associated cost; (2) medi-
cation and blood product cost, comprising individual drugs,
other medication, and transfusions; and (3) other costs
incurred by transportation, materials, medical infrastructure,
diagnostic procedures in microbiology, and housing. The
direct bottom-up cost per day of hospital stay was
calculated by dividing the total direct medical cost (in €)
by mean total length of hospital stay (in days). For certain
direct medical and non-medical resource consumption
items, proxies were estimated based on German medical
flat rates, as no bottom-up cost data were available [11]. For
the present analysis, patients were censored in the event of
treatment change due to transfer, treatment failure, or
change in AML therapy.
Cost of antifungal agents in the German hospital setting
in 2007
Drugcosts[including19%valueaddedtax(VAT)]forapatient
with a weight of 70 kg were calculated based on official list
prices and high-user hospital pharmacy drug acquisition cost
for caspofungin and L-AmB, respectively. The calculations
were based on the dosing scheme used in the RCT [7], i.e.,
c a s p o f u n g i n7 0m go nd a y1f o l l o w e db yc a s p o f u n g i n5 0m g
for 12 days, or L-AmB 3 mg/ kg bodyweight for 12.5 days.
Reimbursement of antifungal agents in the German hospital
setting in 2007
In 2005, two types of reimbursement were introduced into
the German hospital reimbursement system: Besides DRG-
based reimbursement and independently of clinical com-
plexity, certain drugs that cannot be allocated to a single
DRG but typically used in a tertiary care hospital setting are
covered by the system. The actual reimbursement depends
on the total amount of the respective medicine used for the
individual patient. This ‘supplementary reimbursement’
(Zusatzentgelt) scheme, based on the average high-user
hospital pharmacy drug acquisition costs (including VAT),
is adjusted annually. Each year, the individual hospital has
to negotiate the amount of this reimbursement with the
statutory health insurance funds (Krankenkassen). As this
supplementary reimbursement forms part of the overall
budget of the hospital, its value to the individual hospital is
not yet clear. On the other hand, individual departments
may benefit greatly from the scheme, as medications
covered are reimbursed in addition to DRGs and an
Table 1 Breakdown of direct costs (€) from a bottom-up study of 71 hospital stays (20 patients with acute myeloid leukemia) in a hematology–
oncology tertiary care hospital ward in 2002
(All cost in €) Mean SE 95% CI Median
Staff
Medical care
a 1,386 60 1,266–1,506 1,299
Nursing care
a 3,153 147 2,860–3,446 2,843
Medication/blood products
Individual drugs
b 5,999 503 4,995–7,002 4,067
Other drugs
c 449 20 410–489 421
Transfusion
d 1,666 131 1,405–1,927 1,092
Transplantation 1,331 224 883–1,778 0
Other
Materials
e 720 37 647–793 660
Medical infrastructure
f 1376 60 1,257–1,496 1,290
Microbiology 589 24 542–636 572
Base cost
g 1,806 79 1,649–1,963 1,692
Total 19,039 998 17,050–21,029 16,067
SE Standard error; 95% CI 95% confidence interval; calculated with SAS PROC SURVEYMEANS
aIncluding ward stand-by duty, temporary help, and extra hours
bDrugs ordered for the individual patients ≥1€ based on ward total pharmacy consumption
cFlat rate for “ward requirement” drugs and drugs <1€
dIncluding blood substitutes
eAll patient-related medical ward supplies
fAll non-patient-related medical ward supplies
gHousing and general service
Ann Hematol (2008) 87:311–319 313increase in overall budget is therefore possible. In 2007,
both caspofungin and L-AmB were included in this scheme
[12]. In 2007, the reimbursement per stay in hospital for a
total dose of L-AmB of between 2,150 and 3,150 mg is
€4,744.70, while that for a total dose of caspofungin of
between 600 and 700 mg is €5,150.90.
Number needed to treat for one patient to be harmed
Laupacis et al. [13] introduced the concept of the number
needed to treat (NNT) to observe one less adverse event.
NNT is the reciprocal of the absolute risk reduction. Based
on the outcome of the original RCT [7], we calculated the
NNT for one patient to be harmed for nephrotoxicity. To
assess uncertainty of the estimation, a 95% confidence
interval was obtained by inverting and exchanging the
confidence limits for the absolute risk reduction as
described by Bender according to Wilson [14].
Health economic evaluation
Perspective
The analysis assessed the direct medical and non-medical
costs of resource utilization attributable to prolongation of
hospital stay due to L-AmB-related nephrotoxicity. Respon-
sibility for managing hematology–oncology patients with
invasive fungal infections lies primarily with the tertiary care
sector. Therefore, the perspective of the tertiary care sector,
rather than that of German statutory health insurance or
society, was chosen for the present analysis.
Economic analysis framework
Our evaluation of costs and its consequences is based on (1)
difference in nephrotoxicity rates in the RCT [7]; (2) data
on prolongation of hospital stay due to AmB and lipid
formulation-related nephrotoxicity in hematology–oncolo-
gy patients in Europe [8]; (3) cost of antifungal agents [15];
and (4) bottom-up data on direct cost of hospital stay per
day in hematology–oncology in Germany. All costs were
adjusted for inflation and calculated in 2007 euros [16]. As
the evaluation focuses on short-term cost and consequences
with immediate benefits, economic analyses were undis-
counted. Calculations (for a 70-kg patient; see Table 2)
were based on patient-individualized doses per treatment
episode per treatment arm of the RCT [7], the official
German price list [15], and German high-user hospital
pharmacy drug acquisition cost including 19% VAT
(provided by German university hospital pharmacists).
Table 2 Data input for the calculations
Parameter Caspofungin group Liposomal amphotericin B group
a
Nephrotoxicity risk
b 2.6%
c (95% CI 1.55–4.24; n=547) 11.5%
c (95% CI 9.05–14.53; n=522)
Absolute risk difference
c −8.9% (95% CI 5.9–12.0)
Treatment days per stay
c 13 12.5
Drug cost according to official German price list (2007, incl. 19% VAT)
Per bottle, 70 mg €799.57
d –
Per bottle, 50 mg €630.68
e €209.43
Per day of treatment (see above) €879.61
Total €8,368 €10,995
Drug cost according to high-user hospital pharmacy drug acquisition cost (2007, incl. 19% VAT)
Per bottle, 70 mg €559.30 (day 1) –
Per bottle, 50 mg €428.40 (days 2–13) €96.99
Per day of treatment (see above) €407.34
Total €5,700 €5,092
Supplementary reimbursement (Zusatzentgelt, 2007)
Treatment-related code (mg range applicable) 39.12 (600 mg–<700 mg) 43.16 (2,150 mg–<3,150 mg)
Supplementary reimbursement (ZE) €5,151 €4,745
ZE Zusatzentgelt, a treatment-related extra reimbursement scheme that is paid besides DRG for medicines and devices that cannot be allocated to
a single DRG. In 2007, L-AmB as well as caspofungin are covered under this scheme.
aLiposomal amphotericin B, 3 mg per kg bodyweight per day, 70-kg patient
bCaspofungin vs liposomal amphotericin B
cData from the original publication
dDay 1
eDays 2–13
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evaluation
Modifying the work done by Spiegelhalter et al. [17], a
two-stage Monte Carlo simulation on binominal and
Gaussian random variables from separate studies with
comparable populations was performed. Stage 1 included
(1) simulation of the binominal distribution of the initial
risk of nephrotoxicity due to L-AmB and caspofungin use,
respectively [7], followed by simulation of absolute risk
reduction and (2) simulation of the density of another
normally distributed random variable ‘prolonged length of
hospital stay due to L-AmB use’ [8]. In stage 2, ‘cost of
hospital stay per day in hematology–oncology’ (gamma
distributed random variable) and ‘high-user hospital phar-
macy drug acquisition cost of the respective antifungal
agent’ (constant) were added to the model. Freely available
WinBUGS 1.4.1 software based on SAS 9.1.3 was used to
calculate mean, standard error, median, confidence inter-
vals [18, 19], and the probability of cost savings [20]. The
per diem total hospital costs at which the use of
caspofungin were estimated to be cost-neutral compared
to L-AmB were obtained from the inverse of the extra days
in hospital due to nephrotoxicity multiplied by the
difference in cost for caspofungin and L-AmB before and
after accounting for their supplementary reimbursement
[19]. Results obtained by WinBUGS were imported into
SAS and formatted and processed into SAS data sets to
produce tables [21].
Results
Number needed to treat for one patient to be harmed
The NNTs for one patient to be harmed by nephrotoxicity
for L-AmB vs caspofungin from the RCT [7] was 12 (95%
CI 8–17).
Direct cost of hematology–oncology stay in a tertiary
hospital in Germany
Seventy-one hospital stays (mean, 34 days; minimum,
1 day; and maximum, 96 days) of 20 patients with AML
treated between 2001 and 2003 were included. Overall
staff times and associated costs, medication and blood
product costs, and other costs are shown in Table 1.
Treatment cost for AML at Bonn university also included
costs for induction and consolidation therapy. Patients
undergoing auto-SCT are included. The direct bottom-up
cost per hospital stay per day in the hematology unit at
Bonn University Hospital, Germany was estimated at €626
(95% CI 550–702), equivalent to €587 in 2002 (95% CI
€516–€658).
Overall medical care cost consisted of one physician (one
full time equivalent/FTE), two interns (two FTE), and two
consultants (0.45 and 0.05 FTE). Night duties and extra
hours were included. Cost of nursing care, in Germany
traditionally characterized by cost per nursing staff regula-
tion minute, was €0.51/min. Total direct cost of autologous
SCT was €20,679 (2002). This includes materials (€4,154),
stem cell mobilization and separation (€10,744), preparatory
steps before re-infusion (€5,239), and quality assurance
measures (€542). In 2002, the total number of hospital-
izations in this hematology ward at Bonn university was 338,
and the total number of myelosuppressive chemotherapy
cycles was 154, respectively.
As access to the cost of some medical service units of
the hospital was limited, the following costs were estimated
based on German medical flat rates [11]: (1) medical
services, including electrocardiograms and X-rays, mean
€265 (95% CI 230–301); (2) consultancy fees (internal
calculation), mean €25 (95% CI 20–31); (3) hematology
lab, mean €185 (95% CI 169–201); (4) immunology lab,
mean €40 (95% CI 27–52); and (5) other lab services, mean
€323 (95% CI 275–370).
Incremental cost due to nephrotoxicity
Based on the data from the RCT [7] and the LEAD study
[8], the nephrotoxicity-related prolongation of hospital stay
per patient was 0.48 days (95% CI 0.14–0.88). Based on
the bottom-up cost data presented in this paper, this results
in an additional cost of €298 (2007; 95% CI 89–554) for
each patient treated with L-AmB.
Based on the official German price list (2007; including
19% VAT) [15], the difference in cost of medication is
€2,627 in favor of caspofungin (see Table 2).
Based on high-user hospital pharmacy drug acquisition
cost (2007; including 19% VAT), the difference in cost of
medication is €608 in favor of L-AmB. With consideration
of supplementary reimbursement (Zusatzentgelt), at a direct
cost per day of hospital stay of €428 (95% CI €162; €809)
or more the incremental cost due to L-AmB-related
nephrotoxicity [7] offsets the higher frequent user acquisi-
tion cost of caspofungin. Without consideration of supple-
mentary reimbursement (Zusatzentgelt) of both L-AmB and
caspofungin, respectively, this figure was ≥€1,284 (95%
CI €479; €2,449). Based on the point estimates and
variances of the costing study presented in this paper, the
cost savings per patient treated with caspofungin com-
pared to L-AmB is estimated at €96, ranging from savings
of €352 up to incremental cost of €113, with 95%
confidence (see Table 3). The probability of savings was
79% (Figs. 1 and 2).
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Systemic fungal infections are a major cause of mortality and
morbidity in patientswith hematologic diseases and persistent
neutropenia [1–3]. Infections caused by organisms of the
genera Aspergillus and Candida constitute a challenge for
physicians responsible for the care of these patients [2–4].
The studies from which our calculations are based [7, 8]a n d
the cost study presented in this paper were performed in
comparable populations at high risk for systemic fungal
infections. Both the products under discussion are approved
for use in the indication under consideration.
The RCT upon which the calculations are based [7]
showed the efficacy of caspofungin to be non-inferior to
that of L-AmB. As caspofungin was better tolerated than L-
AmB [7], the present analysis focuses on the most clinically
relevant tolerability endpoint, which, according to the
literature, is the nephrotoxicity associated with antifungal
agents [7, 8, 22, 23].
According to the international literature on this subject,
the cost of AmB-associated nephrotoxicity in hematology–
oncology patients amounts to US$24,756 to 41,083 with
projected cost of treating L-AmB associated impaired renal
function per patient at risk of US$3,173 [24]. On the other
hand, in a single-center study conducted in the USA,
Harbarth et al. [25] were unable to identify any increase in
costs or any prolongation of hospital stay despite increased
mortality. In contrast to the data presented in this paper, all
the studies referred to use ‘top-down’ approaches [24–26],
which allocate a total budget to specific services and thus
provide less precise estimates [9]. Moreover, the findings of
these studies are based on tariffs and fees applicable in the
various countries concerned and therefore cannot be extrap-
olated to the German health system. We deliberately
Table 3 Bayesian model outputs
Parameter Caspofungin Liposomal amphotericin B Difference
a
Analysis of the original head-to-head trial
NNT for one patient to be harmed – 12 (95% CI 9–17) n. a.
Additional stay per treated patient per NNT for one patient to be harmed
Bootstrap calculation; days – 0.48 (95% CI 0.14–0.88) n. a.
Cost per additional stay per patient per day due to amphotericin B-related nephrotoxicity
At direct cost of €626 per day –€ 298 (95% CI €89–€554) n. a.
Total cost at cost per day of hospital stay of €626
Drug cost (incl. 19% VAT) €5,700 €5,092 €608
Incremental cost due to nephrotoxicity - €298 (95% CI €89–€ 554) −€298 (95% CI −€554–−€89)
./. Supplementary reimbursement €5,151
b €4,745
c −€406
Cost €549 €645 (95% CI €436–€901)* −€96 (95% CI −352–113)
d
aCost of caspofingin./.cost of L-AmB
bSupplementary reimbursement ZE 39.12
cSupplementary reimbursement ZE 43.16
dIn favor of caspofungin. Probability that total difference is ≤€0 is 79% (see Fig. 2).
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Fig. 1 Density function of the
cost difference
between using caspofungin
and L-AmB in hematology–
oncology in Germany
316 Ann Hematol (2008) 87:311–319undertook a micro-costing (‘bottom-up’) approach, evaluat-
ing the situation for all the costs of individual items related to
the treatment and care of AML. This approach provides a
more specific insight into the relationships between charac-
teristics of activities and their costs and the relative
importance of separate activities [9]. The published literature
contains only one article that specifies the ‘bottom-up’ costs
per day of hospital stay in Germany [27], albeit for intensive
care. To our knowledge, the microeconomic analysis pre-
sented in this paper is the first of its kind in hematology–
oncology that refers to the German health system.
The results of the present analysis are based upon data
derived from the year 2002 (before the introduction of
DRGs in Germany). We have adjusted cost for inflation.
The transition from per diem charges to diagnosis related
charges—which started in 2003 and will be completed
nationwide in 2010—may have initiated efforts to optimize
the costing structure in German hospitals.
We believe that our analyses are conservative. Firstly,
the proportion of patients who developed L-AmB related
nephrotoxicity defined as a twofold increase in serum
creatinine compared to baseline was similar in the random-
ized controlled trial—which gave rise to the number needed
to harm of L-AmB vs caspofungin—and the LEAD study
[7, 8]. The LEAD study, however, found already a 1.5-fold
increase in serum creatinine compared to baseline—which
comprises a far higher proportion of patients [8, 23]—to be
associated with longer stays in hospital [8]. In addition, no
account was taken of the other tolerability advantages of
caspofungin [7], e.g., fewer side effects during the infusion.
On the other hand, L-AmB associated nephrotoxicity may
also lead to dose reductions and thus lower cost of some
antibiotics and other medications.
Secondly, the data from Bonn University Hospital
presented in this paper exclude the costs of allogeneic stem
cell transplantation, as patients were transferred to another
tertiary care hospital to undergo that procedure. The cost of
transplantation as a component of direct medical costs may
therefore have been considerably underestimated in the
present analysis. In two Norwegian studies, the mean cost
of autologous and allogeneic stem cell transplantation was
found to be US$32,160 (2001) [28] and US$106,825
(1999) [29], respectively.
In the year 2002, the mean direct cost of treating AML at
Bonn University Hospital was found to be €19,039. Hospital
funding in Germany is a case-mix system based on
diagnosis-related groups (DRGs) in which the basic DRG
indicates the underlying condition. Secondary diagnoses are
indicated by patient clinical complexity levels (PCCL).
Discrepancies between DRG reimbursement and real cost
are possible and have been identified by the German
competence network ‘Acute and chronic leukaemias’ [4].
Thus, where the underlying condition is AML and the
clinical complexity level is increased due to the presence of
systemic fungal infection, a hospital stay of 34 days in the
year 2007 is to be reimbursed by €9,669, [10, 30].
The present analysis refers to the costs and reimburse-
ment of systemic antifungal agents in tertiary care hospitals.
The recent introduction of supplementary reimbursement
(Zusatzentgelt) makes such reimbursement possible [11]
when a definable service of no fixed assignment occurs
sporadically across a number of DRGs and causes
significant costs to the system as a whole. As such
supplementary reimbursements are paid besides DRG pay-
ments but within the total budget of the individual hospital,
this form of reimbursement spares the base rate of tertiary
care hospitals and makes these hospitals competitive
compared to lower levels of service provision at a high
level of quality care. Thus, the supplementary reimburse-
ment (Zusatzentgelt) in Germany helps to maintain the
budget of the individual hospital, and it helps the department
caring for an individual patient to get the expenses covered.
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Fig. 2 Cumulative probability
of the cost-difference between
using caspofungin and L-AmB
in hematology–oncology in
Germany
Ann Hematol (2008) 87:311–319 317The development of nephrotoxicity during treatment
with liposomal and other formulations of AmB prolongs
hospital stays [8]. From the perspective of the hospital
operator, the additional costs due to this nephrotoxicity are
therefore directly dependent on the mean direct medical
cost per day of hospital stay. Based on the better tolerability
of caspofungin, high-user hospital pharmacy drug acquisi-
tion cost including 19% VAT and the outcome of the
costing study presented in this paper, we estimated that with
a probability of 79%, use of this substance is more cost-
effective for German hospitals than use of L-AmB. In
general terms, caspofungin was found to be cost-saving
compared to L-AmB at any direct medical cost greater than
€428 per day of hospital stay. If supplementary reimburse-
ment (Zusatzentgelt, 2007) is excluded from the calculation,
which is usually not done, this break-even point is €1,284
per day of hospital stay. On the other hand, these figures
could be considerably lower if other efficacy and safety
endpoints [7] were included in the calculation.
The present analysis of the risk and costs of nephrotoxicity
for tertiary care hospitals with hematology–oncology depart-
ments is based on the best available evidence. The present
system of DRG-based reimbursement for the treatment of
AML per se does not cover all costs. The better renal
tolerability of caspofungin compared to L-AmB results in
shorter hospital stays and therefore more economical use of
health care resources. The data presented in this paper show
thatonthebasisofnephrotoxicityalone,useofcaspofunginin
hematology–oncology departments in Germany is at least
cost-neutral compared to use of L-AmB.
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